Entries by Ruben Böhler

HETEROGENEITY OF RESPONSE TO IMMUNE CHECKPOINT BLOCKADE IN HYPERMUTATED EXPERIMENTAL GLIOMAS

Research findings related to UNITE work package B01 Intrinsic malignant brain tumors, such as glioblastomas are frequently resistant to immune checkpoint blockade (ICB) with few hypermutated glioblastomas showing response. Modeling patient-individual resistance is challenging due to the lack of predictive biomarkers and limited accessibility of tissue for serial biopsies. Here, Michael Platten et al. investigate […]

27. February 2020 by

SUPERIORITY OF TEMOZOLOMIDE OVER RADIOTHERAPY FOR ELDERLY PATIENTS WITH RTK II METHYLATION CLASS, MGMT PROMOTER-METHYLATED MALIGNANT ASTROCYTOMA

Research findings related to clinical trial development within UNITE O6-methylguanine DNA-methyl transferase (MGMT) promoter methylation status is predictive for alkylating chemotherapy, but there are non-benefitting subgroups. The long-term update of NOA-08 compared efficacy and safety of radiotherapy (RT, n=176) and temozolomide at 7/14 days (TMZ, n=193) in patients >65 years with anaplastic astrocytoma or glioblastoma. […]

27. February 2020 by

GLUTAMATERGIC SYNAPTIC INPUT TO GLIOMA CELLS DRIVES BRAIN TUMOUR PROGRESSION

Research findings related to UNITE work package A01 A network of communicating tumour cells that is connected by tumour microtubes mediates the progression of incurable gliomas. Moreover, neuronal activity can foster malignant behaviour of glioma cells by non-synaptic paracrine and autocrine mechanisms. Here Kuner et al. report a direct communication channel between neurons and glioma […]

27. February 2020 by